Invitrogen plans to launch a new drug-screening platform early in the second quarter as a key part of its strategy to build its nascent screening-services business, company officials told BioCommerce Week.

The SelectScreen Profiling and Screening Services platform was initially launched in 2004 and builds off of the firm's kinase-screening business. The new platform — enabled by SSi Robotics' automation technology — will enable Invitrogen researchers to perform assays more quickly at higher throughput, the officials said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.